Back to Journals » International Journal of Nanomedicine » Volume 7

Inhaled chemotherapy in lung cancer: future concept of nanomedicine

Authors Zarogoulidis P, Chatzaki, Porpodis K, Domvri K, Hohenforst-Schmidt W, Goldberg E, Karamanos, Zarogoulidis K

Received 17 January 2012

Accepted for publication 2 February 2012

Published 22 March 2012 Volume 2012:7 Pages 1551—1572

DOI https://doi.org/10.2147/IJN.S29997

Review by Single anonymous peer review

Peer reviewer comments 2



Paul Zarogoulidis1, Ekaterini Chatzaki2, Konstantinos Porpodis1, Kalliopi Domvri1, Wolfgang Hohenforst-Schmidt3, Eugene P Goldberg4, Nikos Karamanos5, Konstantinos Zarogoulidis1
1Pulmonary Department, "G Papanikolaou" General Hospital, Aristotle University of Thessaloniki, Greece; 2Pharmacology Laboratory, Medical School, Democritus University of Thrace, Alexandroupolis, Greece; 3II Medical Clinic, Hospital Coburg, University of Wurzburg, Coburg, Germany; 4Biomaterials Science and Engineering, Department of Materials Science and Engineering, University of Florida, FL; 5Biochemistry Laboratory, Department of Chemistry, University of Patra, Greece

Abstract: Regional chemotherapy was first used for lung cancer 30 years ago. Since then, new methods of drug delivery and pharmaceuticals have been investigated in vitro, and in animals and humans. An extensive review of drug delivery systems, pharmaceuticals, patient monitoring, methods of enhancing inhaled drug deposition, safety and efficacy, and also additional applications of inhaled chemotherapy and its advantages and disadvantages are presented. Regional chemotherapy to the lung parenchyma for lung cancer is feasible and efficient. Safety depends on the chemotherapy agent delivered to the lungs and is dose-dependent and time-dependent. Further evaluation is needed to provide data regarding early lung cancer stages, and whether regional chemotherapy can be used as neoadjuvant or adjuvant treatment. Finally, inhaled chemotherapy could one day be administered at home with fewer systemic adverse effects.

Keywords: inhaled chemotherapy, carriers, transducers

Creative Commons License © 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.